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Materials and Methods 
System Preparation 
Crystal structures & PTP. Protein residues within 5 Å of the GAG ligand, if present, were 
selected from the PDB. Hydrogen atoms were added with tleap (1) and CHARMM charges were 
assigned to each atom. The system was minimized using the DREIDING force field (2). 
NgR. Five homology models for full-length NgR1, 2, and 3 were obtained using ROSETTA (3). 
Each model was conjugate gradient minimized (5000 steps) and then allowed to relax in the 
presence of water and counter ions with 5 ns of MD. MD was performed using NAMD in four 
steps, as described later in the MD section. Briefly, first, a water box bounding the protein was 
minimized with the protein kept fixed. Second, 0.5 ns of NPT MD were performed on the water 
box. Third, the entire systems were minimized. Finally, 5 ns of NPT MD were performed on the 
entire system. For each initial conformation, the conformation closest to the average structure 
from the 5 ns MD was minimized and the lowest energy conformation was selected for each 
isoform.  
Ligand Preparation  
For the four validation systems, the ligand found in the crystal structure was used. The CS-A, 
CS-D, and CS-E structures used for docking to the non-validation systems were based on a CS-A 
hexasaccharide crystal structure (4), while the heparin structures for docking to the non-
validation systems are based on a heparin 18-mer NMR structure. For CS-A and heparin, it was 
necessary only to extend or truncate the structure to the appropriate length. We prepared CS-D 
and CS-E by extending the CS-A structure to a 12-mer, modifying the sulfation pattern, 
optimizing the side chains, and performing 5 ns of molecular dynamics (MD) in aqueous 
solution. MD system preparation and simulation parameters are further outlined in the supporting 
information. The structure closest to the average during MD was selected as the conformation for 
docking. This conformation was then truncated to a hexa- or octa-saccharide by removing sugars 
from both the reducing and non-reducing ends. This step was necessary because the terminal 
saccharides display high variability in torsion angles during MD that are unphysical (inconsistent 
with possible movements) for an extended polysaccharide (5, 6). 
All crystal structure ligands were prepared by identifying the appropriate DREIDING atom types 
and assigning Mulliken charges from Density Functional Theory (DFT) calculations [B3LYP 
flavor using the 6-311G** basis set) using Jaguar.  
Heparin and CS ligands for the predicted systems (RPTP, NgR1, NgR2, and NgR3) were 
generated from available 18-mer heparin NMR structures (6) and a 6-mer CS-A (4) crystal 
structure as mentioned above. The heparin and CS-A structures were truncated or extended as 
needed for docking. Generating CS-D and CS-E required modifying the sulfation pattern of an 
extended 12-mer CS-A structure. 
The sulfation pattern was modified using the Maestro software, Mulliken charges were 
calculated, and the MacroModel Conformational Search tool was used to sample the sidechain 
torsions (the sugar backbone was kept fixed). The resulting conformations were minimized using 
DREIDING and MPSim with Surface Generalized Born (SGB) solvation. The lowest-energy 
conformation was then selected for MD. 
The AMBER package was used to place the 12-mer in a water box with a number of sodium ions 
added to neutralize the ligand charge. Dynamics was performed using NAMD (7) in four steps as 
described in the next section. Briefly, first, the water box was minimized with the ligand kept 
fixed. Second 0.5 ns of MD were performed on the water box. Third, the entire system was 
minimized. Finally, 5 ns of MD were performed on the entire system. The final ligand 
conformation for docking was the conformation closest to the average structure from the 5 ns 
MD. The 12-mer was truncated for docking by removing the terminal sugars. In addition, these 
MD trajectories were used to generate multiple ligand conformations for docking to sample 
conformational changes in the GAG backbone during docking. A ligand conformation was 
output for each MD step, and all conformations were clustered based on ligand RMSD into 12 
groups. The lowest energy conformation from each group was used for docking.  
GAG-Dock Summary: 
We perform a two-step process for each GAG-protein complex, we first identify likely GAG 
binding sites on the target protein using coarse docking and then we re-dock using find docking 
to identify strongly bound poses.  
In the first step, for “coarse-docking” we dock a single GAG conformation to the entire protein 
surface to identify likely binding sites. This configuration is chosen by minimizing the ligand in 
the solvent. Here, docking to the ‘alanized’ structure allows us to quickly scan the entire protein 
for putative GAG binding sites by optimizing the long-range Coulomb interactions.  
In the second step, for “fine-grained” we re-dock to the best coarse regions to identify specific, 
strongly bound poses. In this step, we sample ligand conformations more completely allowing 
rotations about single bonds to accommodate the intrinsic flexibility of the GAG ligand. We 
selected 12 conformations to have low energies while remaining diverse, as described under 
ligand preparation. Then do rigid docking of this ensemble of 12 GAG ligand conformations. 
Finally, all final energies for all poses for all 12 conformations are ranked together by total 
energy and the best 100 are minimization before identifying the top docked structure for each 
GAG-protein complex. These methods are detailed further below and in the SI. 
DarwinDock 
The concept behind DarwinDock (8-13) is (1) to generate a complete set of poses for the binding 
site while minimizing the number of energy evaluations, (2) then to collect these into a smaller 
sets containing all poses likely to be important, (3) then to evaluate the binding energy of this 
relatively small set to find the best poses, while ensuring that no poses are missed that might 
prove to be important.  
Pose generation is accomplished by iteratively generating poses (but no energies) using 
DOCK 6 (14) and clustering them into families using our Closest-Neighbor Seeded clustering 
algorithm (described below). Our usage of DOCK 6 is very simplistic, utilizing only the bump 
filter. We follow the default settings for generating the bump grid for DOCK 6 and set the bump 
cutoff to 5. Two calls to DOCK 6 are generally made. First, a request for 40,000 poses is made to 
determine the approximate percentage of poses that will pass the DOCK bump filter. Then a 
second request for poses is made, based on the percent of poses passing the bump test so that 
enough poses are returned to be sufficient for the iterative completeness cycle. Initially the first 
5000 poses are clustered with a 2 Å diversity, then the next 5000 poses are added and 
reclustered, leading an increased number of families. This process is continued in increments of 
5000 poses until the number of new families represents less than 5% of the total number of 
families at that point. 
Due to the computational difficulty of dealing with GAG ligands – which are considerably 
larger than normal small-molecule ligands for which DarwinDock was developed – leading to 
correspondingly increased search volumes, we restrict the number of poses during this iterative 
completeness cycle to 50,000. Furthermore, it is generally not possible to request more than 15 
million poses (sometimes fewer) from DOCK6 before memory-limitations intercede. As a result, 
most regions reach the 50,000 pose limit before reaching the 5% new families threshold. Other 
regions may fall well short of 50,000 poses due to their geometry and memory limitations. 
After generating a complete set of poses, or the largest set within our computational limits, 
we score all family heads (generally ~2000). For each family the central pose (based on the 
RMSD) is denoted as the family head. The protein-ligand interaction energy of each family head 
is evaluated using the DREIDING forcefield with MPSim (15, 16). DREIDING partitions non-
bond energies into Coulomb, hydrogen-bond, and van der Waals (vdW) contributions. For GAG-
Dock the interaction energy is the sum of all ligand-protein Coulomb and hydrogen-bond 
energies plus 10% of the vdW energy. Including only 10% of the vdW energy allows for strong 
polar interactions with the protein with moderate clashes that can be resolved during side chain 
optimization. Not including the VDW energy results in poses with severe, unresolvable clashes 
with the protein, while including the full VDW energy results in poses that are too far from the 
protein and make poor contact. 
After evaluating the interaction energy for the family heads, we eliminate the worst 90% of 
the families. Next, we evaluate the interaction energy for all children in the remaining 10% of 
families. From these children we select best 100 based on binding energy. Eliminating 90% of 
the families without evaluating all of their child poses allows for a large fraction of the complete 
set of poses to be eliminated without the time-consuming energy evaluation. 
The 100 selected poses are then further refined with side chain optimization using SCREAM 
(17). Any side chain that was alanized prior to docking is now restored and optimized (“de-
alanized”) by SCREAM. Simultaneously, any polar or charged side chain in the binding site is 
also optimized by SCREAM, resulting in 100 unique sets of side chain conformations each 
adapted to a specific ligand pose. Each complex is then energy optimized for 10 steps of 
conjugate gradient minimization. The minimized complexes are then scored using the “snap” 
binding energy, which is the total energy of the protein and the total energy of the ligand 
subtracted from the total energy of the complex, all calculated using DREIDING and MPSim. 
We then eliminated half of these complexes based on these energies. The remaining half was 
optimized with an additional 50 steps of conjugate gradient minimization. These fully-minimized 
complexes were rescored again, and the top one or two poses identified for analysis. 
Closest-Neighbor Seeded Ligand Clustering 
The Closest-Neighbor Seeded (CNS) ligand clustering algorithm uses a RMSD-based metric to 
cluster ligands into families and to assign family heads. First, all pairwise ligand RMSDs were 
calculated (ignoring hydrogen atoms). These pairwise RMSDs were placed in a list ordered from 
smallest RMSD to largest. The pair of ligands with the smallest RMSD constitutes the seed for 
the first family/cluster. Proceeding down the list of pairs i and j, the following operations were 
carried out: 
1. If pose i and pose j do not belong to a pre-existing family, then a new family is seeded 
2. If pose i belongs to family A and pose j does not (or vice versa): 
If the RMSD of pose j to all members of family A is less than the diversity RMSD, then 
pose j is added to family A 
3. If pose i belongs to family A and pose j belongs to family B: 
If the RMSD of pose i to all members of family B is less than the diversity RMSD, and if 
the RMSD of pose j to all members of family A is less than the diversity RMSD, then the 
two families are merged into a single family 
The pose with the lowest RMSD to the rest of the members is designated as the family head. If a 
family only has two members then the family head is chosen randomly. 
Force Field 
All force field calculations during docking – with the exception of sidechain optimizations – 
were performed using the DREIDING force field and the MPSim molecular dynamics code. 
DREIDING uses a three-body hydrogen bond term that allows a more precise analysis of the 
energetics. It also eliminates the need of SHAKE constraints that must be used with the 2-body 
hydrogen bonds used in most force fields. 
Side Chain Optimization 
Side chain optimization was performed using the SCREAM program (17) (using the DREIDING 
force field). 
Sphere Generation 
Spheres were generated using a modified sphgen program (14). Specifically, two sets of spheres 
were generated for each protein: 
The “normal” set: 
 Use a 1.4 Å probe radius in the dms molecular surface program  
 Use dotlim=–0.9 in sphgen 
 Use 1.4 Å minimum and 10 Å maximum sphere radii in sphgen 
The “restriction” set: 
 Use 2.8 Å probe radius in dms 
 Use dotlim=–0.9’ in sphgen 
 Use 2.8 Å minimum and 10 Å maximum sphere radii in sphgen 
The final set of spheres is taken from the “normal” set with the criteria that a sphere must be 
within 2.8 Å of a sphere from the “restriction” set. 
The final set of spheres was partitioned into overlapping boxes having 20 Å sides and allowing 5 
Å overlap.  
As mentioned above, we assign electrostatic potential values to the spheres. The electrostatic 
potential for the protein is generated using APBS (18) and mapped onto the generated spheres. 
The electrostatic potential for a given sphere is taken from the value from the nearest APBS grid 
point. 
Sphere Clustering 
In order to reduce the number of spheres in each region to a computationally-manageable 
number, the spheres are clustered using the CNS algorithm, with each sphere treated as a single-
atom ligand. The clustering diversity is set at 0.25 and increased until the total number of 
families is less than 150, or until the diversity is 3.00. For sphere families with 3 or more 
spheres, the family head is kept to represent the family. For sphere families of 2 spheres, the 
coordinates are averaged. 
Molecular Dynamics (MD) 
The MD simulations were carried out using NAMD, a parallel MD code designed for 
computationally demanding biomolecular systems. The CHARMM force field was used for the 
protein and ligands. The TIP3P force field was used for water. NAMD employs periodic 
boundary conditions to remove surface effects. The full electrostatic interactions within this 
periodic system is calculated using the particle-mesh Ewald summation method. The long-range 
electrostatic and van der Waals interactions were cut off at 12 Å (with spline smoothing).  
The calculations were performed under isothermal-isobaric conditions (NPT) at 310 K and 1 
atm. The temperature was controlled using Langevin dynamics (with a coupling coefficient of 5 
ps
-1
) and the pressure is maintained using a Langevin-Hoover barostat. A time step of 1 fs was 
used throughout this study. 
Simulations. The MD is carried out in 4 steps: 
a) The water atoms and counter-ions were conjugate gradient minimized for 5000 steps while 
keeping the protein and ligand atoms fixed. This allows for the water and counter ions to 
remove any bad contacts with each other and the protein or the ligand, prior to MD. 
b) Then the water and counter ion atoms were equilibrated under NPT conditions (310 K and 1 
atm) for 0.5 ns, while keeping the protein and ligand fixed. This allows the and waters and 
counter ions to equilibrate in the presence of the protein and to fill any gaps around the 
protein created due to system setup. 
c) Next, the full system (protein-ligand-water) was minimized for 5000 steps, allowing the 
protein and ligand to adjust to the equilibrated water and counter ions. 
d) Finally, the full system is equilibrated for at least 5 ns under NPT conditions, of which only 
the last 5 ns is used for dynamical analysis. Snapshots are saved every 1 ps. 
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Supporting Figures 
Figure S1 – Summary of docking validations for GAG-protein systems with available crystal 
structures. The resolution of the x-ray structure is given along with the heavy-atom RMSD 
between the predicted and x-ray position of the ligand  
Figure S2 – Structure of FGF1 [PDB: 2AXM, resolution 3.00 Å] with predicted and crystal 
heparin hexamer ligands (magenta: predicted, green: crystal).  Residues in the binding site with 
significant deviations from the crystal are labeled (cyan: predicted, orange: crystal). Ligand 
RMSD is 0.70 Å. 
Figure S3 – Structure of FGF1 [PDB: 2AXM, res. 3.00 Å] with predicted heparin hexamer 
ligand (magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate hydrogen bonding 
and salt bridges between ligand and protein.  The predicted ligand has excellent agreement with 
the crystal ligand, RMSD: 0.70 Å.   
Figure S4 – Structure of FGF2 [PDB: 1BFB, res. 1.90 Å] with predicted heparin tetramer ligand 
(magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate hydrogen bonding and salt 
bridges between ligand and protein.  The predicted ligand has excellent agreement with the 
crystal ligand, RMSD: 0.70 Å.   
Figure S5 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain A with predicted heparin 
hexamer ligand (magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate hydrogen 
bonding and salt bridges between ligand and protein.  The predicted ligand has excellent 
agreement with the crystal ligand, RMSD: 1.51/0.75 Å.   
Figure S6 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain B with predicted heparin 
hexamer ligand (magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate hydrogen 
bonding and salt bridges between ligand and protein.  The predicted ligand has excellent 
agreement with the crystal ligand, RMSD: 1.51/0.75 Å.   
Figure S7 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain C with predicted heparin 
hexamer and octamer ligands (magenta) and 5 Å binding site shown (cyan).  Dashed lines 
indicate hydrogen bonding and salt bridges between ligand and protein.  The predicted ligand has 
excellent agreement with the crystal ligand, RMSD: 1.51/0.75 Å.   
Figure S8 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain C with predicted heparin 
hexamer and octamer ligands (magenta) and 5 Å binding site shown (cyan).  Dashed lines 
indicate hydrogen bonding and salt bridges between ligand and protein.  The predicted ligand has 
excellent agreement with the crystal ligand, RMSD: 1.51/0.75 Å.   
Figure S9 – Structure of α-antithrombin-III [PDB: 1E03, res. 2.90 Å] with predicted heparin 
analog pentamer ligand (magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate 
hydrogen bonding and salt bridges between ligand and protein.  The predicted ligand has 
excellent agreement with the crystal ligand, RMSD: 0.60 Å.   
Figure S10 - Plots of nonbond energies for residues in the (A) FGF1, (B) FGF2, (C) FGF2-
FGFR1 Chain A complex, (D) FGF2-FGFR1 Chain B complex, and (E) α-Antithrombin-III 
binding sites in complex with a heparin ligand in the crystal versus docked structure. Residues 
with significant deviations from the trend are labeled. 
Figure S11 – Per-residue energetic contributions in the FGF1/heparin predicted (left) and crystal 
(right) structures. [PDB: 2AXM, res. 3.00 Å, RMSD: 0.70 Å].   
Figure S12 – Per-residue energetic contributions in the FGF2/heparin predicted (left) and crystal 
(right) structures. [PDB: 1BFB, res. 1.90 Å, RMSD: 0.70 Å]. 
Figure S13 – Per-residue energetic contributions in the FGF2-FGFR1/heparin predicted (left) 
and crystal (right) structures for chains A and B. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 Å].   
Figure S14 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-A predicted (left) 
and crystal (right) structures for chain C. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 Å].   
Figure S15 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-A predicted (left) 
and crystal (right) structures for chain D. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 Å].   
Figure S16 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-B predicted (left) 
and crystal (right) structures for chain C. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 Å].   
Figure S17 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-B predicted (left) 
and crystal (right) structures for chain D. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 Å].   
Figure S18 – Per-residue energetic contributions in the Antithrombin-III/heparin analog 
predicted (left) and crystal (right) structures. [PDB: 1E03, res. 2.90 Å, RMSD: 0.60 Å]. 
Figure S19 – RPTPσ.  (A) Ig1 and Ig2 domains of RPTPσ. (B) Electrostatic potential surface. 
(C-F) Predicted structures of CS-A, CS-D, CS-E, and heparin after docking and molecular 
dynamics.   
Figure S20 – Predicted structure of CS-E hexamer (magenta) bound to RPTPσ with 5 Å binding 
site shown (cyan).  Dashed lines indicate hydrogen bonding and salt bridges between ligand and 
protein.   
Figure S21 – Predicted structure of heparin hexamer (magenta) bound to RPTPσ with 5 Å 
binding site shown (cyan). Dashed lines indicate hydrogen bonding and salt bridges between 
ligand and protein.   
Figure S22 – Per-residue energetic contributions in the predicted RPTPσ/CS-A (left) and 
RPTPσ/CS-D (right) structures.   
Figure S23 – Per-residue energetic contributions in the predicted RPTPσ/CS-E (left) and 
RPTPσ/heparin (right) structures. 
Figure S24 – Electrostatic potential surfaces of (A) NgR1, (B) NgR2, and (C) NgR3.  Note the 
lack of positive charge on NgR2, but strong positive charge on NgR1 and NgR3.   
Figure S25 – NgR1.  (A) Structure of NgR1. (B) Electrostatic potential surface showing strong 
positive charge. (C-F) Predicted structures of CS-A, CS-D, CS-E, and heparin after docking and 
molecular dynamics. (G-H) Detailed view of CS-E and heparin predicted structures. 
Figure S26 – Detail of predicted NgR1/CS-A structure after docking and dynamics with CS-A 
hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding 
and salt bridges between ligand and protein.  Overall placement on protein shown in inset. 
Figure S27 – Detail of predicted NgR1/CS-D structure after docking and dynamics with CS-D 
hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding 
and salt bridges between ligand and protein.  Overall placement on protein shown in inset.   
Figure S28 – Detail of predicted NgR1/CS-E structure after docking and dynamics with CS-E 
hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding 
and salt bridges between ligand and protein.  Overall placement on protein shown in inset.   
Figure S29 – Detail of predicted NgR1/heparin structure after docking and dynamics with 
heparin hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate hydrogen 
bonding and salt bridges between ligand and protein.  Overall placement on protein shown in 
inset.   
Figure S30 – Per-residue energetic contributions in the predicted NgR1 structures for CS-A, CS-
D, CS-E, and heparin. 
Figure S31 – NgR3.  (A) Structure of NgR3. (B) Electrostatic potential surface. (C-F) Predicted 
structures of CS-A, CS-D, CS-E, and heparin after docking and molecular dynamics. (G-H) 
Detailed view of CS-E and heparin predicted structures.   
Figure S32 – Detail of predicted NgR3/CS-A structure after docking and dynamics with CS-A 
hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding 
and salt bridges between ligand and protein.  Overall placement on protein shown in inset.   
Figure S33 – Detail of predicted NgR3/CS-D structure after docking and dynamics with CS-D 
hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding 
and salt bridges between ligand and protein.  Overall placement on protein shown in inset.   
Figure S34 – Detail of predicted NgR3/CS-E structure after docking and dynamics with CS-E 
hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate hydrogen bonding 
and salt bridges between ligand and protein.  Overall placement on protein shown in inset.   
Figure S35 – Detail of predicted NgR3/heparin structure after docking and dynamics with 
heparin hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate hydrogen 
bonding and salt bridges between ligand and protein.  Overall placement on protein shown in 
inset.   
Figure S36 – Per-residue energetic contributions in the predicted NgR3 structures for CS-A, CS-
D, CS-E, and heparin. 
Figure S37 – Predicted sets of mutations to either increase (left) or decrease (right) binding of 
ligands to RPTPσ.  Note that none of the sets show improved binding for heparin.  Changes in 
binding energy are shown relative to the wild-type structures in both absolute change (kcal/mol) 
and in terms of percent change. 
Figure S38 – Single residue mutation data for RPTPs. Values show change in binding energy 
(kcal/mol) relative to wild-type structures. Values are shown both for the change in hydrogen 
bonding for the specific mutated residue as well as the overall change in the full cavity binding 
energy. The cavity binding energy is further separated into hydrogen bonding + van der Waals or 
Coulomb energy.   
Figure S39 – Predicted sets of mutations to either increase (left) or decrease (right) binding of 
ligands to NgR1.  Note that none of the sets show improved binding for CS-E.  Changes in 
binding energy are shown relative to the wild-type structures in both absolute change in binding 
energy (kcal/mol) and in terms of percent change. 
Figure S40 – Single residue mutation data for NgR1. Values show change in binding energy 
(kcal/mol) relative to wild-type structures. Values are shown both for the change in hydrogen 
bonding for the specific mutated residue as well as the overall change in the full cavity binding 
energy. The cavity binding energy is further separated into hydrogen bonding + van der Waals or 
Coulomb energy. 
Figure S41 – Predicted sets of mutations to either increase (left) or decrease (right) binding of 
ligands to NgR3. Changes in binding energy are shown relative to the wild-type structure in both 
absolute change (kcal/mol) and in terms of percent change. 
Figure S42 – Single residue mutation data for NgR3. Values show change in binding energy 
(kcal/mol) relative to wild-type structures. Values are shown both for the change in hydrogen 
bonding for the specific mutated residue as well as the overall change in the full cavity binding 
energy. The cavity binding energy is further separated into hydrogen bonding + van der Waals or 
Coulomb energy. 
  
 
 
 
 
 
 PDB Resolution (Å) RMSD* (Å) 
FGF1 2AXM 3.00 0.70 
FGF2 1BFB 1.90 0.70 
FGF2-FGFR1 A 1FQ9 3.00 1.51 
FGF2-FGFR1 B   0.75 
α-ATIII 1EO3 2.90 0.60 
 
   *RMSD between docked and crystal structures 
 
 
Figure S1 – Summary of docking validations for GAG-protein systems with available crystal 
structures. The resolution of the x-ray structure is given along with the heavy-atom RMSD 
between the predicted and x-ray position of the ligand 
 
 
 
 
 
Figure S2 – Structure of FGF1 [PDB: 2AXM, resolution 3.00 Å] with predicted and crystal 
heparin hexamer ligands (magenta: predicted, green: crystal).  Residues in the binding site 
with significant deviations from the crystal are labeled (cyan: predicted, orange: crystal). 
Ligand RMSD is 0.70 Å.  See also: Figure 2, S3, S10, and S11. 
 
Figure S3 – Structure of FGF1 [PDB: 2AXM, res. 3.00 Å] with predicted heparin hexamer 
ligand (magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate hydrogen 
bonding and salt bridges between ligand and protein.  The predicted ligand has excellent 
agreement with the crystal ligand, RMSD: 0.70 Å.  See also: Figure 2, S2, S10, and S11. 
 
 
 
Figure S4 – Structure of FGF2 [PDB: 1BFB, res. 1.90 Å] with predicted heparin tetramer 
ligand (magenta) and 5 Å binding site shown (cyan).  Dashed lines indicate hydrogen 
bonding and salt bridges between ligand and protein.  The predicted ligand has excellent 
agreement with the crystal ligand, RMSD: 0.70 Å.  See also: Figure 2, S10, and S12. 
 
 
Figure S5 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain A with predicted 
heparin hexamer ligand (magenta) and 5 Å binding site shown (cyan).  Dashed lines 
indicate hydrogen bonding and salt bridges between ligand and protein.  The predicted 
ligand has excellent agreement with the crystal ligand, RMSD: 1.51/0.75 Å.  See also: 
Figure 2, S6-S8, S10, and S13-S17. 
 
 Figure S6 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain B with predicted 
heparin hexamer ligand (magenta) and 5 Å binding site shown (cyan).  Dashed lines 
indicate hydrogen bonding and salt bridges between ligand and protein.  The predicted 
ligand has excellent agreement with the crystal ligand, RMSD: 1.51/0.75 Å.  See also: 
Figure 2, S5, S7-S8, S10, and S13-S17. 
 Figure S7 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain C with predicted 
heparin hexamer and octamer ligands (magenta) and 5 Å binding site shown (cyan).  
Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein.  The 
predicted ligand has excellent agreement with the crystal ligand, RMSD: 1.51/0.75 Å.  See 
also: Figure 2, S5-S6, S8, S10, and S13-S17. 
 Figure S8 – Structure of FGF2-FGFR1 [PDB: 1FQ9, res. 3.00 Å] chain C with predicted 
heparin hexamer and octamer ligands (magenta) and 5 Å binding site shown (cyan).  
Dashed lines indicate hydrogen bonding and salt bridges between ligand and protein.  The 
predicted ligand has excellent agreement with the crystal ligand, RMSD: 1.51/0.75 Å.  See 
also: Figure 2, S5-S7, S10, and S13-S17. 
 Figure S9 – Structure of α-Antithrombin-III [PDB: 1E03, res. 2.90 Å] with predicted 
heparin analog pentamer ligand (magenta) and 5 Å binding site shown (cyan).  Dashed 
lines indicate hydrogen bonding and salt bridges between ligand and protein.  The 
predicted ligand has excellent agreement with the crystal ligand, RMSD: 0.60 Å.  See also: 
Figure 2, S10, and S16. 
 Figure S10 - Plots of nonbond energies for residues in the (A) FGF1, (B) FGF2, (C) FGF2-
FGFR1 Chain A complex, (D) FGF2-FGFR1 Chain B complex, and (E) α-Antithrombin-III 
binding sites in complex with a heparin ligand in the crystal versus docked structure. 
Residues with significant deviations from the trend are labeled. 
 
 Figure S11 – Per-residue energetic contributions in the FGF1/heparin predicted (left) and 
crystal (right) structures. [PDB: 2AXM, res. 3.00 Å, RMSD: 0.70 Å].  See also: Figure 2, S2, 
S3, and S10. 
 Figure S12 – Per-residue energetic contributions in the FGF2/heparin predicted (left) and 
crystal (right) structures. [PDB: 1BFB, res. 1.90 Å, RMSD: 0.70 Å]. See also: Figure 2, S4, 
and S10. 
 Figure S13 – Per-residue energetic contributions in the FGF2-FGFR1/heparin predicted 
(left) and crystal (right) structures for chains A and B. [PDB: 1FQ9, res. 3.00 Å, RMSD: 
1.51/0.75 Å].  See also: Figure 2, S5-S8, S10, and S14-S17. 
 Figure S14 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-A predicted 
(left) and crystal (right) structures for chain C. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 
Å].  See also: Figure 2, S5-S8, S10, S13, and S15-S17. 
 Figure S15 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-A predicted 
(left) and crystal (right) structures for chain D. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 
Å].  See also: Figure 2, S5-S8, S10, S13, S14, S16, and S17. 
 Figure S16 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-B predicted 
(left) and crystal (right) structures for chain C. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 
Å].  See also: Figure 2, S5-S8, S10, S13-S15, and S17. 
 Figure S17 – Per-residue energetic contributions in the FGF2-FGFR1/heparin-B predicted 
(left) and crystal (right) structures for chain D. [PDB: 1FQ9, res. 3.00 Å, RMSD: 1.51/0.75 
Å].  See also: Figure 2, S5-S8, S10, and S13-S16. 
 Figure S18 – Per-residue energetic contributions in the Antithrombin-III/heparin analog 
predicted (left) and crystal (right) structures. [PDB: 1E03, res. 2.90 Å, RMSD: 0.60 Å]. See 
also: Figure 2, S9, and S10. 
  
Figure S19 – RPTPσ.  (A) Ig1 and Ig2 domains of RPTPσ. (D) Electrostatic potential 
surface. (B, C, E, F) Predicted structures of CS-A, CS-D, CS-E, and heparin after docking 
and molecular dynamics.  See also: Figure 3, S20-S23, S37, and S38. 
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 Figure S20 – Predicted structure of CS-E hexamer (magenta) bound to RPTPσ with 5 Å 
binding site shown (cyan).  Dashed lines indicate hydrogen bonding and salt bridges 
between ligand and protein.  See also: Figure 3, S19, S21-S23, S37, and S38. 
 Figure S21 – Predicted structure of heparin hexamer (magenta) bound to RPTPσ with 5 Å 
binding site shown (cyan). Dashed lines indicate hydrogen bonding and salt bridges 
between ligand and protein.  See also: Figure 3, S19-S20, S22-S23, S37, and S38. 
 Figure S22 – Per-residue energetic contributions in the predicted RPTPσ/CS-A (left) and 
RPTPσ/CS-D (right) structures.  See also: Figure 3, S19-S21, S23, S37, and S38. 
  
Figure S23 – Per-residue energetic contributions in the predicted RPTPσ/CS-E (left) and 
RPTPσ/heparin (right) structures. See also: Figure 3, S19-S22, S37, and S38. 
 Figure S24 – Electrostatic potential surfaces of (A) NgR1, (B) NgR2, and (C) NgR3.  Note 
the lack of positive charge on NgR2, but strong positive charge on NgR1 and NgR3.  See 
also: Figure 4, and S25-S36 and S39-S42. 
  
Figure S25 – NgR1.  (A) Structure of NgR1. (E) Electrostatic potential surface showing 
strong positive charge. (B, C, F, G) Predicted structures of CS-A, CS-D, CS-E, and heparin 
after docking and molecular dynamics. (D, H) Detailed view of CS-E and heparin predicted 
structures. See also: Figure 4, S24, S26-S31, S39, and S40. 
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 Figure S26 – Detail of predicted NgR1/CS-A structure after docking and dynamics with 
CS-A hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate 
hydrogen bonding and salt bridges between ligand and protein.  Overall placement on 
protein shown in inset.  See also: Figure 4, S24-S25, S27-S31, S39, and S40. 
 
Figure S27 – Detail of predicted NgR1/CS-D structure after docking and dynamics with 
CS-D hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate 
hydrogen bonding and salt bridges between ligand and protein.  Overall placement on 
protein shown in inset.  See also: Figure 4, S24-26, S27-S31, S39, and S40. 
 Figure S28 – Detail of predicted NgR1/CS-E structure after docking and dynamics with 
CS-E hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate 
hydrogen bonding and salt bridges between ligand and protein.  Overall placement on 
protein shown in inset.  See also: Figure 4, S24-S27, S29-S31, S39, and S40. 
 Figure S29 – Detail of predicted NgR1/heparin structure after docking and dynamics with 
heparin hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate 
hydrogen bonding and salt bridges between ligand and protein.  Overall placement on 
protein shown in inset.  See also: Figure 4, S24-S28, S30-S31, S39, and S40. 
 Figure S30 – Per-residue energetic contributions in the predicted NgR1 structures for CS-
A, CS-D, CS-E, and heparin. See also: Figure 4, S24-S29, S31, S39, and S40. 
  
 
Figure S31 – NgR3.  (A) Structure of NgR3. (E) Electrostatic potential surface. (B, C, F, G) 
Predicted structures of CS-A, CS-D, CS-E, and heparin after docking and molecular 
dynamics. (D, H) Detailed view of CS-E and heparin predicted structures.  See also: Figure 
4, S24, and S32-S36, S41, and S42. 
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 Figure S32 – Detail of predicted NgR3/CS-A structure after docking and dynamics with 
CS-A hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate 
hydrogen bonding and salt bridges between ligand and protein.  Overall placement on 
protein shown in inset.  See also: Figure 4, S24, S31, S33-S36, S41, and S42. 
 Figure S33 – Detail of predicted NgR3/CS-D structure after docking and dynamics with 
CS-D hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate 
hydrogen bonding and salt bridges between ligand and protein.  Overall placement on 
protein shown in inset.  See also: Figure 4, S24, S31, S32, S34-S36, S41, and S42. 
 Figure S34 – Detail of predicted NgR3/CS-E structure after docking and dynamics with 
CS-E hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate 
hydrogen bonding and salt bridges between ligand and protein.  Overall placement on 
protein shown in inset.  See also: Figure 4, S24, S31-S33, S35, S36, S41, and S42. 
 Figure S35 – Detail of predicted NgR3/heparin structure after docking and dynamics with 
heparin hexamer (magenta) and 5 Å binding site (cyan) shown.  Dashed lines indicate 
hydrogen bonding and salt bridges between ligand and protein.  Overall placement on 
protein shown in inset.  See also: Figure 4, S24, S31-S34, S36, S41, and S42. 
Figure S36 – Per-residue energetic contributions in the predicted NgR3 structures for CS-
A, CS-D, CS-E, and heparin. See also: Figure 4, S24, S31-S35, S41, and S42. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S37 – Predicted sets of mutations to either increase (left) or decrease (right) binding 
of ligands to RPTPσ.  Note that none of the sets show improved binding for heparin.  
Changes in binding energy are shown relative to the wild-type structures in both absolute 
change (kcal/mol) and in terms of percent change.  
 
 
 
 
 
 
 
Figure S38 – Single residue mutation data for RPTPs. Values show change in binding 
energy (kcal/mol) relative to wild-type structures. Values are shown both for the change in 
hydrogen bonding for the specific mutated residue as well as the overall change in the full 
cavity binding energy. The cavity binding energy is further separated into hydrogen 
bonding + van der Waals or Coulomb energy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S39 – Predicted sets of mutations to either increase (left) or decrease (right) binding 
of ligands to NgR1.  Note that none of the sets show improved binding for CS-E.  Changes 
in binding energy are shown relative to the wild-type structures in both absolute change in 
binding energy (kcal/mol) and in terms of percent change. 
NGR1 
Figure S40 – Single residue mutation data for NgR1. Values show change in binding energy 
(kcal/mol) relative to wild-type structures. Values are shown both for the change in 
hydrogen bonding for the specific mutated residue as well as the overall change in the full 
cavity binding energy. The cavity binding energy is further separated into hydrogen 
bonding + van der Waals or Coulomb energy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S41 – Predicted sets of mutations to either increase (left) or decrease (right) binding 
of ligands to NgR3. Changes in binding energy are shown relative to the wild-type structure in 
both absolute change (kcal/mol) and in terms of percent change. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S42 – Single residue mutation data for NgR3. Values show change in binding energy 
(kcal/mol) relative to wild-type structures. Values are shown both for the change in 
hydrogen bonding for the specific mutated residue as well as the overall change in the full 
cavity binding energy. The cavity binding energy is further separated into hydrogen 
bonding + van der Waals or Coulomb energy. 
 
 
 
 
 
 
 
 
 
 
